Literature DB >> 23363331

Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.

Michelle Friedman1, James Spalding, Smita Kothari, You Wu, Elyse Gatt, Luke Boulanger.   

Abstract

OBJECTIVE: Adenosine, dipyridamole, and regadenoson are pharmacologic stress agents used in myocardial perfusion imaging (MPI), to diagnose and monitor coronary artery disease. Clinical studies suggest that regadenoson has pharmacologic properties that simplify the MPI procedure through availability to a wider range of patients and easier administrative requirements. This study assesses the operational advantages and laboratory efficiency associated with the use of regadenoson compared to adenosine and dipyridamole.
METHODS: A web-based survey of 141 nuclear medicine technologists working in US-based cardiovascular imaging laboratories from June-July 2009. MAIN OUTCOME MEASURES: Descriptive statistics measured the adenosine, dipyridamole, and regadenoson cohorts. Bivariate analyses compared the overall and staff-specific time to conduct an MPI test. The site-specific sub-groups were defined by hospital vs non-hospital setting, hours of operation, number of SPECT cameras, and number of full-time equivalent staff, including nurses, nuclear technologists, physicians, and nurse practitioners/physician assistants.
RESULTS: The total time to conduct an MPI test was shortest with regadenoson 156 (46) min compared to adenosine and dipyridamole 182 (63) and 191 (61) min, respectively. Time from regadenoson administration to the start of the imaging session, including dose calculation and infusion time, was 14.2 min less than adenosine, and 12.0 min less than dipyridamole. The time to manage adverse events was shortest if it occurred with regadenoson compared to adenosine and dipyridamole, with minor exceptions. Due to the nature of survey implementation, possible recall bias may limit the results. Some differences in procedures times may be attributable to differences in laboratories' protocols.
CONCLUSIONS: Overall time savings and time savings stratified by operational ability (number of staff, number of SPECT cameras, hours of operation) translate to a more efficient utilization of laboratory resources when using regadenoson compared to adenosine and dipyridamole. Regadenoson is the most efficient pharmacologic stress agent compared to adenosine and dipyridamole.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23363331     DOI: 10.3111/13696998.2013.772057

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  5 in total

1.  Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2.

Authors:  Jill J Weyers; Venkat Ramanan; Ahsan Javed; Jennifer Barry; Melissa Larsen; Krishna Nayak; Graham A Wright; Nilesh R Ghugre
Journal:  NMR Biomed       Date:  2021-11-17       Impact factor: 4.044

2.  Pharmacological stress myocardial perfusion imaging after an inadequate exercise stress test.

Authors:  Parija Sharedalal; Perry Gerard; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2021-05-25       Impact factor: 3.872

3.  Predictors and Diagnostic Significance of the Adenosine Related Side Effects on Myocardial Perfusion SPECT/CT Imaging.

Authors:  Nilüfer Yıldırım Poyraz; Elif Özdemir; Barış Mustafa Poyraz; Zuhal Kandemir; Mutlay Keskin; Şeyda Türkölmez
Journal:  Mol Imaging Radionucl Ther       Date:  2014-10-05

4.  Comparative Performances of Dipyridamole and Regadenoson to Detect Myocardial Ischemia using Cardiac Cadmium-Zinc-Telluride Single-Photon Emission Computerized Tomography.

Authors:  Fayçal Ben Bouallçgue; Catherine Nganoa; Jonathan Vigne; Denis Agostini; Alain Manrique
Journal:  J Clin Imaging Sci       Date:  2018-11-15

5.  Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test.

Authors:  Hongbo Yang; Elizabeth Faust; Emily Gao; Sakshi Sethi; Therese M Kitt; Rita M Kristy; James R Spalding; Yanqing Xu
Journal:  J Nucl Cardiol       Date:  2021-03-11       Impact factor: 3.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.